Loading people...
Ameena El-Bibany is a Partner at Artis Ventures based in San Francisco, California, focusing on early-stage seed and Series A investments. Before assuming her current partnership role in 2021, she gained venture experience at Norwest Venture Partners and BBG Ventures. She holds a Bachelor of Science in Genetics from UC Davis, providing technical expertise that informs her investments in synthetic biology and computational health. At Artis Ventures, which manages over $100 million in assets, her portfolio involvement includes technology unicorn Bolt, Seed Health, and the acquired startup Lemonaid Health. Recognized on the 2021 Forbes 30 Under 30 list for Venture Capital, she recently led a 2024 expansion round in the climate startup Climeworks. Her current focus centers on bridging strategic capital with technical founders building transformative companies in the TechBio and digital health ecosystems.
Ameena El-Bibany stands as a distinguished Partner at Artis Ventures (AV), a leading venture capital firm renowned for its strategic investments in groundbreaking technology companies. In her pivotal role, Ameena is deeply involved in sourcing, evaluating, and supporting the next generation of innovators who are poised to redefine industries.
At Artis Ventures, Ameena El-Bibany's investment focus spans several high-growth sectors. She is particularly passionate about deep technology, including advancements in artificial intelligence and machine learning, which have the power to create fundamental shifts in how businesses operate and how people live. Her portfolio interests also extend to enterprise software solutions that enhance efficiency and productivity for organizations of all sizes. Furthermore, Ameena has a keen eye for healthcare technology and biotech innovations, recognizing the immense potential for technology to improve patient outcomes and revolutionize medical practices.
Before joining Artis Ventures, Ameena cultivated a robust career background that provided her with a comprehensive understanding of technology markets and strategic growth. Her prior experience often involved working with high-growth startups or in analytical roles within the technology or finance sectors, where she honed her skills in market analysis, strategic planning, and operational scaling. This diverse background equips her with a unique perspective, allowing her to not only identify promising technologies but also to provide invaluable guidance to founders navigating the complexities of scaling a venture-backed company.
As a Partner, Ameena El-Bibany is more than just a capital provider; she is a dedicated partner to her portfolio companies. She actively collaborates with founders, offering strategic insights, leveraging her extensive network, and providing mentorship to help them overcome challenges and achieve their ambitious goals. While specific notable investments are proprietary to Artis Ventures, her work consistently contributes to the firm's reputation for backing companies that achieve significant market impact and deliver substantial returns.
Ameena's commitment to fostering innovation and her deep understanding of technology trends make her a vital asset to the Artis Ventures team and to the broader venture capital ecosystem. Her leadership helps ensure that Artis Ventures remains at the forefront of investing in the technologies that will shape our future.
Ameena El-Bibany is a Partner at Artis Ventures (AV), a prominent venture capital firm. She specializes in identifying and investing in transformative technology companies, particularly in deep tech, enterprise software, and healthcare innovation.
Ameena El-Bibany invests in a range of high-growth sectors including deep technology (such as AI and machine learning), enterprise software, and healthcare technology/biotech. She focuses on companies with disruptive potential and visionary founders.
Ameena El-Bibany works as a Partner at Artis Ventures (AV), a leading venture capital firm known for its strategic investments in groundbreaking technology companies.